MedCity News

JULY 2, 2024

The post Eli Lilly Alzheimer’s Drug Lands FDA Approval, Introducing Competition to Eisai’s Leqembi appeared first on MedCity News. In addition to slowing cognitive decline and disease progression, clinical trial results showed that amyloid beta plaques were reduced to the point where some patients could stop taking the infused therapy.

Competition 115

Competition FDA Patients Biopharma 115

Eversana Intouch

NOVEMBER 9, 2023

Back in 2003, drugs from large pharma companies made up 36% of the late-stage R&D pipeline. These data are astonishing, given the perception that Big Pharma is the main driver of biopharma innovation. Yet, we know small-to-mid-sized pharma launches face a unique set of challenges. Not anymore. Download POV

Pharma 105

Pharma Biopharma Competition Marketing 105

MedCity News

NOVEMBER 7, 2023

The Federal Trade Commission says more than 100 patents from 10 biopharma companies are improperly listed in the FDA’s official publication of approved products. Such listings delay generic competition, which reduces consumer choice and keeps prices high, the regulator said.

Biopharma 130

Biopharma Competition FDA Pharma 130

PM360

FEBRUARY 1, 2024

Embarking on the journey from product development to market success in the biopharma industry is no small feat. The landscape is highly competitive with new prescription medications launching worldwide each year. However, this journey is fraught with challenges as revealed by an in-depth analysis.

Biopharma 59

Biopharma Competition Prescription Marketing 59

MedCity News

AUGUST 12, 2024

FDA approval of Ascendis Pharma’s Yorvipath is just in time for patients with hypoparathyroidism as Takeda Pharmaceutical will soon stop making the only drug therapy for the rare disorder. But competition could come from others, including an AstraZeneca peptide in late-stage development.

FDA 113

FDA Pharma Competition Pharmaceutical 113

MedCity News

JANUARY 28, 2024

The big three insulin manufacturers have cut prices across their product lineups, but potential competition from other biosimilar insulins is still in earlier stages of development. Insulin prices have long been a pain point for diabetics.

Competition 110

Competition Patients Manufacturing Biopharma 110

MedCity News

FEBRUARY 6, 2024

However, the Phase 2 results showed only “clinically meaningful” improvement in resolving liver fibrosis, a key measure of the drug’s potential competitiveness in a crowded field of contenders. Eli Lilly reported 74% of patients treated with tirzepatide achieved resolution of metabolic dysfunction-associated steatohepatitis, or MASH.

Competition 97

Competition Patients Biopharma Pharma 97

MedCity News

JANUARY 22, 2024

If Ionis can commercialize this drug, competition would include products from Takeda Pharmaceutical and BioCryst Pharmaceuticals. In its Phase 3 test, Ionis Pharmaceuticals drug donidalorsen reduced the frequency of swelling attacks caused by the rare disease hereditary angioedema.

Competition 94

Competition Pharmaceutical FDA Biopharma 94

European Pharmaceutical Review

AUGUST 22, 2022

However, China and India are set to be fierce competition over the next decade, with 30 percent of respondents suggesting they would offshore >50 percent of clinical trials and operations to India, China or other lower-cost countries over the next five years.

Biopharma 98

Biopharma Manufacturing Marketing Competition 98

MedCity News

JULY 14, 2024

MiRecule, winner in the biopharma track of MedCity News’s Pitch Perfect startup competition, is now pursuing a Series A round of financing. RNA therapies developer miRecule is partnered with Sanofi on the development of a treatment for facioscapulohumeral muscular dystrophy, or FSHD.

Biopharma 85

Biopharma Competition Pharma 85

pharmaphorum

AUGUST 5, 2022

Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. The pace of innovation in biopharma has rocketed over the last two years, with vaccines, new antivirals, and therapies delivered at an unprecedented pace.

Biopharma 52

Biopharma Marketing Pharma Relationship management 52

Pharmaceutical Technology

JULY 29, 2022

As the full consequences of the COVID-19 virus started to emerge, and many industries found themselves having to either suspend operations or move to remote working, the biopharma sector found itself on the front line facing unprecedented challenges. R&D ecosystem - Index score 6.54/10.

Biopharma 59

Biopharma Manufacturing Government Engineering 59

MedCity News

NOVEMBER 19, 2024

Merck said topline Phase 3 results show an injectable version of Keytruda met the main goal of non-inferiority compared to the intravenously infused formulation that is the pharma giant’s top-selling product. Injectable Keytruda could help Merck compete against coming competition from biosimilars.

Competition 74

Competition Pharma Biopharma 74

MedCity News

FEBRUARY 23, 2023

FDA approval of Sanofi hemophilia A drug Altuviiio provides patients with a therapeutic option that lasts longer than most other products available, including one already marketed by the French pharma giant. Altuviiio also gives Sanofi a way to better compete against blockbuster Roche drug Hemlibra.

Competition 103

Competition FDA Patients Pharma 103

MedCity News

AUGUST 17, 2022

The move means Sanofi is out of the competitive chase to develop a so-called “oral SERD” therapy for patients with a certain type of breast cancer. Sanofi breast cancer drug amcenestrant has failed in a Phase 3 clinical trial, leading the pharmaceutical giant to discontinue all clinical development of the small molecule.

Competition 89

Competition Leads Pharmaceutical Patients 89

Clarivate

MAY 8, 2024

Doubling down on strategic therapeutic areas Pharma once again finds itself having to narrow its sights on partnerships that deliver the next blockbuster and enable differentiation from the competition—all while navigating increasing regulatory scrutiny and shifting patient and payer expectations.

Pharma 59

Pharma Biopharma Prospecting Competition 59

MedCity News

DECEMBER 27, 2023

Cytokinetics drug aficamten met the main goal of a pivotal test in obstructive hypertrophic cardiomyopathy. If approved, the daily pill would compete against a Bristol Myers Squibb drug projected to become a blockbuster seller.

Competition 122

Competition Biopharma Pharma 122

PM360

AUGUST 9, 2022

Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. For biopharma, success in this space will require integrated models that are significantly different than what has been used with historic medicines. In oncology, it’s 47% less.

Biopharma 69

Biopharma Marketing Healthcare Healthcare 69

pharmaphorum

NOVEMBER 24, 2022

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA’s decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC). The post Pharma M&A rumour mill grinds out Mirati’s name again appeared first on.

Pharma 104

Pharma Biopharma FDA Competition 104

Clarivate

MAY 31, 2023

A glance at the 2022 top selling drugs for the biggest pharma companies reveals how dependent many large pharmas are on a small basket of products – most acquired through partnerships or acquisitions – that are nearing loss of exclusivity. Pharma is placing bigger bets on a smaller number of therapeutics and technology platforms.

Pharma 52

Pharma Biopharma Medicine Healthcare 52

Pharmaceutical Technology

DECEMBER 20, 2022

trillion in Q3, according to GlobalData’s Pharma Intelligence Center Companies Database. The growing competition from generic drugs presents challenges for the top 20 players placing pressure on drug prices. The top 20 global biopharmaceutical companies exhibited a downward trend in aggregate market capitalisation by 9.1%

Biopharma 52

Biopharma Marketing Competition Sales 52

pharmaphorum

DECEMBER 28, 2022

M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. Since the first wave of consolidation started in 1988, there has been a significant concentration of the pharma industry.

Pharma 112

Pharma Pharmaceutical manufacturing Pharmaceutical Manufacturing 112

European Pharmaceutical Review

OCTOBER 26, 2022

With pharma/biopharma companies looking to select CDMO partners earlier than before, and in a competitive market, what approaches can be adopted? Included in this Guide to: The changing face of outsourcing. Here, EPR explores some recent trends and evolving strategies. Are you leveraging all the information from your QC data?

Biopharma 98

Biopharma Competition Pharma Management 98

MedCity News

JULY 19, 2023

The restructuring of cardiovascular drugmaker Amarin means the layoff of about 30% of staff. Sales of Vascepa, the company’s only commercialized product, have suffered as generic versions gain traction in the market.

Competition 83

Competition Sales Marketing Biopharma 83

MedCity News

JUNE 16, 2023

The FDA approved Roche’s Columvi as a third-line treatment for a type of blood cancer called diffuse large B-cell lymphoma. This new Roche drug will compete against Epkinly, AbbVie’s recently approved DLBCL drug.

Competition 103

Competition FDA Biopharma Pharma 103

PM360

SEPTEMBER 30, 2024

This article outlines how developers can utilize sustainability initiatives to boost revenue, reduce costs, and advance innovation, ensuring a strategic, long-term, and more sustainable position in today’s competitive landscape. Continued innovation is crucial in enhancing sustainability within pharma and the broader biotech industry.

Manufacturing 52

Manufacturing Pharma Pharmaceutical Competition 52

MedCity News

JANUARY 28, 2024

While pharmaceutical companies continue to raise list prices year-over-year, we work behind the scenes to fight the trend by driving competition, negotiating with drugmakers and incentivizing the use of less expensive medicines that deliver the same clinical value.

Competition 116

Competition Medicine Pharma Patients 116

MedCity News

FEBRUARY 26, 2024

Preliminary Phase 2 results show 83% of those treated with Boehringer Ingelheim and Zealand Pharma drug survodutide met the main goal of improvement in the fatty liver disease MASH. Boehringer contends this drug has best-in-class potential in a competitive field that includes an Eli Lilly drug that recently posted positive Phase 2 results.

Competition 99

Competition Pharma Biopharma 99

Clarivate

DECEMBER 19, 2022

Either way, competition over employed providers among Medicare Advantage plans has only begun to heat up and UnitedHealth remains the plan to beat. Medicare provider competition appeared first on Clarivate. To learn more about how Clarivate helps life science companies navigate the fast-changing U.S.

Competition 52

Competition Retail Insurance Marketing 52

pharmaphorum

OCTOBER 20, 2022

Together, these groups compile vast amounts of data, including rich information on patient populations, target customers, and the competitive landscape. Historically, competitive and market analysis data has been stored in spreadsheets. Truly understanding the competitive landscape and market environment.

Competition 93

Competition Marketing Pharma Biopharma 93

MedCity News

JANUARY 23, 2023

The FDA approved TheracosBio’s Brenzavvy as a treatment for type 2 diabetes. But before it won a regulatory nod for controlling blood glucose in adults, it was approved at a different dose (with flavor) as a veterinary product.

Competition 97

Competition FDA Biopharma Pharma 97

MedCity News

JUNE 26, 2023

Pfizer’s Litfulo is the first treatment approved for treating adolescents with severe alopecia areata. The drug’s approval also covers adults, were it will compete against Eli Lilly’s Olumiant.

Competition 101

Competition FDA Biopharma Pharma 101

MedCity News

SEPTEMBER 29, 2023

Preliminary weight loss and safety data for Structure Therapeutics’ drug candidate suggest it’s competitive with other oral GLP-1 targeting contenders from big pharma companies.

Competition 102

Competition Safety Pharma Biopharma 102

MedCity News

MAY 10, 2023

A drug developed by Protalix BioTherapeutics and Chiesi Group is now FDA approved for treating Fabry disease, a rare inherited metabolic disorder. The drug, Elfabrio, is an enzyme replacement therapy.

Competition 93

Competition FDA Biopharma Pharma 93

Pharmaceutical Technology

JUNE 15, 2023

AI in pharma R&D is one of the latest innovations helping teams apply existing knowledge to new problems. Learn about how AI is helping companies right now, what to know about its benefits and challenges, and what’s needed to implement AI in biopharma research. Here are a few ways AI is used in pharma today.

Pharma 52

Pharma Management Networking Manufacturing 52

MedCity News

DECEMBER 13, 2022

Amgen’s Lumakras became the first FDA-approved drug that addresses the elusive KRAS mutation, but Mirati believes its newly approved therapy, Krazati, could be better. The small molecule’s features include the ability to penetrate into the brain, where it can address cancer that has spread to the central nervous system.

Competition 94

Competition FDA Biopharma Pharma 94

Clarivate

OCTOBER 17, 2024

Audience members during the recent Clarivate webinar Emerging Deal Trends in Biotech and Pharma identified three of the biggest challenges they face when securing deals. Finding the right partners Selecting the right partners in pharma dealmaking is crucial to ensuring the success of a partnership.

Pharma 59

Pharma Competition Marketing Healthcare 59